Combination therapy with RT and TIGIT blockade optimized anti-tumor immunity and depletion of CD103 + DCs resulted in a marked reduction in survival and cure rates following combination therapy, suggesting that CD103 + DCs play an important role in regulating treatment response. The gene discussed is ITGAE; the disease is neoplasm.